Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33.

Article  PubMed  Google Scholar 

The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.

Article  Google Scholar 

Nakamura Y, Kawazoe A, Lordick F, et al. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol. 2021;18:473–87.

Article  PubMed  Google Scholar 

Liu Y, Sethi NS, Hinoue T, et al. Comparative molecular analysis of gastrointestinal adenocarcinomas. Cancer Cell. 2018;33:721–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Totoki Y, Saito-Adachi M, Shiraishi Y, et al. Multiancestry genomic and transcriptomic analysis of gastric cancer. Nat Genet. 2023;55:581–94.

Article  CAS  PubMed  Google Scholar 

Ichikawa H, Nagahashi M, Shimada Y, et al. Actionable gene-based classification toward precision medicine in gastric cancer. Genome Med. 2017;9:93.

Article  PubMed  PubMed Central  Google Scholar 

Takeda M, Takahama T, Sakai K, et al. Clinical application of the FoundationOne CDx assay to therapeutic decision-making for patients with advanced solid tumors. Oncologist. 2021;26:e588–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Inagaki C, Maeda D, Hatake K, et al. Clinical utility of next-generation sequencing-based panel testing under the universal health-care system in Japan: a retrospective analysis at a single university hospital. Cancers (Basel). 2021;13:1121.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takeda H, Imoto K, Umemoto K, et al. Clinical utility of genomic profiling tests in patients with advanced gastrointestinal cancers. Target Oncol. 2022;17:177–85.

Article  PubMed  Google Scholar 

Umemoto K, Yamamoto H, Oikawa R, et al. The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. J Natl Cancer Inst. 2022;114:1279–86.

Article  PubMed  PubMed Central  Google Scholar 

Kanda M, Terashima M, Kinoshita T, et al. A multi-institutional study to evaluate the feasibility of next-generation sequencing and genomic analysis using formalin-fixed, paraffin-embedded biopsies of gastric cancer. Gastric Cancer. 2023;26:108–15.

Article  CAS  PubMed  Google Scholar 

Setia N, Wang CX, Lager A, et al. Morphologic and molecular analysis of early-onset gastric cancer. Cancer. 2020;127:103–14.

Article  PubMed  Google Scholar 

Zhou Q, Tao F, Qiu L, et al. Somatic alteration characteristics of early-onset gastric cancer. J Oncol. 2022;2022:1498053.

Article  PubMed  PubMed Central  Google Scholar 

Milbury CA, Creeden J, Yip WK, et al. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE. 2022;17: e0264138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woodhouse R, Li M, Hughes J, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE. 2020;15: e0237802.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.

Article  PubMed  PubMed Central  Google Scholar 

Trabucco SE, Gowen K, Maund SL, et al. A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples. J Mol Diagn. 2019;21:1053–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lechner M, Frampton GM, Fenton T, et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV− tumors. Genome Med. 2013;5:49.

Article  PubMed  PubMed Central  Google Scholar 

Sun JX, He Y, Scanford E, et al. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. PLoS Comput Biol. 2018;14:e1005965.

Article  PubMed  PubMed Central  Google Scholar 

Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang X, Wojtowicz D, Przytycka TM. Detecting presence of mutational signatures in cancer with confidence. Bioinformatics. 2018;34:330–7.

Article  CAS  PubMed  Google Scholar 

Franzese N, Fan J, Sharan R, et al. ScalpelSig designs targeted genomic panels from data to detect activity of mutational signatures. J Comput Biol. 2022;29:56–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Momozawa Y, Sasai R, Usui Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022;8:871–8.

Article  PubMed  PubMed Central  Google Scholar 

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10.

Article  CAS  PubMed  Google Scholar 

Graf RP, Fisher V, Creeden J, et al. Real-world validation of TMB and microsatellite instability as predictive biomarkers of immune checkpoint inhibitor effectiveness in advanced gastroesophageal cancer. Cancer Res Commun. 2022;2:1037–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chao J, Fuchs CS, Shitara K, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7:895–902.

Article  PubMed  PubMed Central  Google Scholar 

Shitara K, Özgüroglu M, Bang YJ, et al. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann Oncol. 2021;32:1127–36.

Article  CAS  PubMed  Google Scholar 

Wu YM, Cieslik M, Lonigro RJ, et al. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell. 2018;173:1770-82.e14.

Article  CAS  PubMed  Google Scholar 

Sokol ES, Pavlick D, Frampton GM, et al. Pan-cancer analysis of CDK12 loss-of-function alterations and their association with the focal tandem-duplicator phenotype. Oncologist. 2019;12:1526–33.

Article  Google Scholar 

Liu H, Liu K, Dong Z. Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery. Cancer Res. 2021;81:18–26.

Article  CAS  PubMed  Google Scholar 

Zhou X, Ji Y, Zhou J. Multiple strategies to develop small molecular KRAS directly bound inhibitors. Molecules. 2023;28:3615.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saito M, Kono K. Landscape of EBV-positive gastric cancer. Gastric Cancer. 2021;24:983–9.

Article  CAS  PubMed  Google Scholar 

Gu Y, Zhang P, Wang J, et al. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy. Cancer Immunol Immunother. 2023;72:1199–208.

Article  CAS  PubMed  Google Scholar 

Carneiro F. Familial and hereditary gastric cancer, an overview. Best Pract Res Clin Gastroenterol. 2022;58–59: 101800.

Article  PubMed  Google Scholar 

Tanaka Y, Chiwaki F, Kojima S, et al. Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities. Nat Cancer. 2021;2:962–77.

Article  CAS  PubMed  Google Scholar